title: Reduction in the intensity rate of appropriate shocks for ventricular arrhythmias with statin therapy.
abstract: Higher rate of implantable cardioverter-defibrillator (ICD) shocks has been associated with increased mortality and morbidity. The aim of our study was to determine whether statins reduced the intensity rate of appropriate shock therapy for ventricular tachycardia/fibrillation in patients with an ICD placed for left ventricular systolic dysfunction. In this retrospective single center analysis, patients with an ejection fraction <or=35% who underwent ICD implantation were divided into treatment and control groups based on statin use. A zero-inflated negative binomial model was used to compare the intensity rate of appropriate ICD shocks between the 2 groups. Characteristics associated with shock-free follow-up were assessed using a stepwise logistic regression model. We found 699 patients eligible for inclusion, with 412 (59%) in the statin treatment group. The adjusted mean intensity rate of shocks was lower in patients on statin therapy (intensity rate ratio = 0.22; 95% confidence interval, 0.12-0.41; P < 0.001). Statin use was associated with a significantly higher probability of shock-free follow-up (odds ratio = 1.64; 95% confidence interval, 1.09-2.48; P = 0.019). In conclusion, statins reduced the intensity rate of appropriate shock therapy for ventricular tachycardia/fibrillation and increased probability of shock-free follow-up in patients with cardiomyopathy. Larger randomized trials are needed to confirm this relationship.
authors.affiliation: Division of Internal Medicine, Michigan State University, East Lansing, MI 48824, USA.
authors.forename: Abhimanyu
authors.initials: A
authors.lastname: Beri
authors.forename: Tahmeed
authors.initials: T
authors.lastname: Contractor
authors.forename: Joseph C
authors.initials: JC
authors.lastname: Gardiner
authors.forename: Sivakumar
authors.initials: S
authors.lastname: Ardhanari
authors.forename: Ranjan
authors.initials: R
authors.lastname: Thakur
mesh_terms: D000368:Aged; D009202:Cardiomyopathies / Q000628:therapy*; D017147:Defibrillators, Implantable; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D012189:Retrospective Studies; D012307:Risk Factors; D017180:Tachycardia, Ventricular / Q000628:therapy*; D016896:Treatment Outcome; D014693:Ventricular Fibrillation / Q000628:therapy*
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors